A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Proof-of-Concept Study of AR08 in the Treatment of Attention Deficit Hyperactivity Disorder in Children (Ages 6 - 17)
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2015
At a glance
- Drugs AR 08 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Arbor Pharmaceuticals
- 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 15 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.